Symposia

シンポジウムTuesday, 27 March 10:05 ～ 11:10 / 13:10 ～ 17:35
Plenary Lecture: Room O Kanazawa Art Hall
Short Presentation for Invited Poster Presentation: Room O Kanazawa Art Hall
Invited Poster Presentation: Event Plaza in Basement of Kanazawa Station Motenashi Dome
第 4 回国際創薬シンポジウム ISMS
4th International Symposium for Medicinal Sciences (ISMS)
10:05 ～ 10:10

10:10 ～ 11:10
Plenary Lecture 1 
27O-ISMS-PL01

Opening Remark

Chairman: Akira OTAKA (Tokushima University)
Chairman: Tohru FUKUYAMA (Nagoya University)

Recent Developments in Strategies and Tactics Towards Complex Secondary Metabolites Including­Human-Derived Natural Products
Erick M. CARREIRA (Swiss Federal Institute of Technology Zurich)
13:10 ～ 14:10
Plenary Lecture 2   
27O-ISMS-PL02

Chairman: Kentaro KOGURE (Tokushima University)

Interfacing Nanomaterials with Biology: From Delivery of siRNA and CRISPR Machinery to Rapid Cell
Phenotyping
Vincent M. ROTELLO (Department of Chemistry, University of Massachusetts - Amherst)
14:15 ～ 17:35
Invited Poster Presentation

14:15 ～ 15:45 Short Presentation for Invited Poster Presentation (Room O)
15:55 ～ 17:35 Poster Presentation (Kanazawa Station Motenashi Dome)
Discussion Odd Number: 15:55 ～ 16:45
		
Even Number: 16:45 ～ 17:35
27O-ISMS01

Generation of Hepatocytes from Human ES/iPS Cells for Medicinal Sciences○Kazuo TAKAYAMA1, Hiroyuki MIZUGUCHI1 (1Laboratory of Biochemistry and Molecular Biology,
Graduate School of Pharmaceutical Sciences, Osaka University)

27O-ISMS02

A Novel Long-Term Culture Method for Activating Cytochrome P450 and Liver-Speciﬁc Function of
Hepatocytes Utilizing a Collagen Vitrigel Membrane Chamber○Ryuji WATARI1, Motoharu KAKIKI1, Ayumi OSHIKATA2, Toshiaki TAKEZAWA2, Chihiro YAMASAKI3,
Yuji ISHIDA3, Chise TATENO3, Yukie KURODA4, Seiichi ISHIDA4, Kazutomi KUSANO1 (1Drug
Metabolism and Pharmacokinetics Tsukuba, Global Drug Metabolism and Pharmacokinetics, Biopharmaceutical
Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 2Division of Biotechnology,
Institute of Agrobiological Sciences, National Agriculture and Food Research Organization, 3R&D department,
PhoenixBio, Co., Ltd., 4Division of Pharmacology, National Institute of Health Sciences)

27O-ISMS03

Translational Research in Drug Development for NASH Using a Cell-based Chemical Screening○Yusuke HIRATA1, Atsushi MATSUZAWA1 (1Laboratory of Health Chemistry, Graduate School of

Pharmaceutical Sciences, Tohoku University)

27O-ISMS04

The Proﬁles of Trastuzumab Deruxtecan (DS-8201a), Topoisomerase I Inhibitor Exatecan-Derivative Based
HER2-Targeting Antibody-Drug Conjugate○Takashi NAKADA1, Hiroyuki NAITO1, Yusuke OGITANI1, Takahiro JIKOH1, Koji MORITA1,Tomomi NAKAYAMA-IWATA1, Chiaki ISHII1, Junko YAMAGUCHI1, Takeshi MASUDA1, Ryo ATSUMI1,
Katsunobu HAGIHARA1, Masataka OITATE1, Yoshihiko FUJISAKI1, Takeshi HONDA1, Yuki ABE1,
Toshinori AGATSUMA1 (1Daiichi Sankyo Co., Ltd.)– 28 –

27O-ISMS05

Endogenous Simian Retrovirus Variations in Vero Cells: Implications for Quality Control of a Human Vaccine
Cell Substrate
Chisato SAKUMA1, Tsuyoshi SEKIZUKA2, Makoto KURODA2, Fumio KASAI3, Kyoko SAITO1,
Masaki IKEDA4, Toshiyuki YAMAJI1, Naoki OSADA4, ○Kentaro HANADA1 (1Department of Biochemistry &Cell Biology, National Institute of Infectious Diseases, 2Pathogen Genomics Center, National Institute of
Infectious Diseases, 3Laboratory of Cell Cultures, National Institutes of Biomedical Innovation, Health andNutrition, 4Graduate School of Information Science and Technology, Hokkaido University)

27O-ISMS06

Diﬀerential Infection Pattern of AAVs in Mouse Retina○Tesshu HORI1,2, Masashi FUKUTOME2,3, Chiseto MAEJIMA1,2, Satoru MORITOH2,4,Kenta KOBAYASHI5, Chieko KOIKE1,2,6,7 (1College of Pharmaceutical Sciences, 2Labolatory for Systems
Neurosciences and Developmental Biology, 3College of Life Sciences, 4Ritsumeikan Global Innovation
Research Organization (R-GIRO), Ritsumeikan University, 5National Institute for Physiological Sciences,
6Graduate School of Life Sciences, 7Center for Systems Vision Science, Organization of Science andTechnology, Ritsumeikan University)

27O-ISMS07

ASP7266, a Novel Antibody against Human Thymic Stromal Lymphopoietin Receptor, in the Treatment ofAllergic Disease○Mako NUMAZAKI1, Kaori HANAOKA1, Emiko IMAMURA1, Masashi MAEDA1, Kazunori ARAI1,
Tetsu SAITO1, Fujiko TAKAMURA1, Hiroshi SUZUKI1, Satoshi KUBO1, Shigetada FURUKAWA1(1Drug Discovery Research, Astellas Pharma Inc.)

27O-ISMS08

Treatment of Ischemic Stroke by Combination Therapy with Liposomal Neuroprotectants and Tissue
Plasminogen Activator○Tatsuya FUKUTA1,2, Tomohiro ASAI2, Kentaro KOGURE1, Naoto OKU2 (1Department of Pharmaceutical
Health Chemistry, Graduate School of Biomedical Sciences, Tokushima University, 2Department of Medical
Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka)

27O-ISMS09

Responsive Nanocaplets Prepared via ‘Oxidative Polymerization’ for Intracellular Delivery of Anionic Proteins○P.K HASHIM1, Kou OKURO1, Takuzo AIDA1 (1School of Engineering, Department of Chemistry andBiotechnology, The University of Tokyo)

27O-ISMS10

Controlled Release of Anticancer Drugs by LSD1 Inhibition○Yosuke OTA1, Yukihiro ITOH1, Takayoshi SUZUKI1 (1Graduate School of Medical Science, Kyoto
Prefectural University of Medicine)

27O-ISMS11

Prediction of Human Pharmacokinetics Using Chimeric Mice with Humanized Liver○Yoichi NARITOMI1, Seigo SANOH2, Shigeru OHTA2 (1Analysis & Pharmacokinetics Research Laboratories,

Astellas Pharma Inc., 2Graduate School of Biomedical and Health Sciences, Hiroshima University)

27O-ISMS12

Natural Product Discovery by Heterologous Expression of Cryptic Biosynthetic Pathway in Aspergillus oryzae○Teigo ASAI1 (1Department of Life Sciences, Graduate school of Arts and Sciences, The University of Tokyo)

27O-ISMS13

Plecomarcolide Analogues Produced by Streptomyces sp. GIC10-1 Isolated from a Marine Sponge Theonella sp.
Yu-Hsin CHEN1,2, Mei-Chin LU2,3, Ching-Feng WENG1, Jimmy KUO2,3, ○Ping-Jyun SUNG2,3 (1Departmentof Life Science and Graduate Institute of Biotechnology, National Dong Hwa University, 2National Museum ofMarine Biology and Aquarium, 3Graduate Institute of Marine Biology, National Dong Hwa University)

27O-ISMS14

Bioinspired Chemical Synthesis of Monomeric and Dimeric Stephacidin A Congeners
Ken MUKAI1, Danilo PEREIRA DE SANT’ANA1, ○Yasuo HIROOKA2, Eduardo V. MERCADO-MARIN1,
David E. STEPHENS1, Kevin G. M. KOU1, Sven C. RICHTER1, Naomi KELLEY1, Richmond SARPONG1(1Department of Chemistry, University of California, Berkeley, 2Ono Pharmaceutical Co., Ltd., Medicinal
Chemistry Research Laboratories)

27O-ISMS15

Discovery of a Novel Inhibitor (ASP8273) of EGFR T790M Mutation○Maiko IIDA1, Takahiro MATSUYA1, Itsuro SHIMADA1, Shigetoshi KIKUCHI1, Kenichi ONDA1,
Hiroaki TANAKA1, Naoki KANEKO1, Hideki SAKAGAMI1, Nobuaki SHINDO1, Shinya MIMASU1,
Yoichi NARITOMI1, Yosuke YAMANAKA1, Tadashi TERASAKA1, Masaaki HIRANO1 (1Astellas Pharma Inc.)– 29 –

27O-ISMS16

Identiﬁcation of Selective TRPM8 Antagonists for the Treatment of Neuropathic Pain
○Masashi OHMI1, Yuji SHISHIDO1, Kazuo ANDO1, Kiyoshi KAWAMURA1, Hiroyuki OHSHIRO1,
Akiyoshi FUJIUCHI1, Akiko YAMADA1, Norikazu GAJA1, Azusa SATO1, Yumi ISOGAI1, Shuzo WATANABE1(1RaQualia Pharma Inc.)

27O-ISMS17

Synthetic Posttranslational Modiﬁcations: A Chemical Catalyst System to Directly Introduce Posttranslational
Modiﬁcations into Endogenous Chromatin○Kenzo YAMATSUGU1,2, Yoshifumi AMAMOTO1,2, Yuki AOI1,2, Nozomu NAGASHIMA1,
Hiroki SUTO1,2, Daisuke YOSHIDOME3, Yasuhiro ARIMURA4, Akihisa OSAKABE4, Daiki KATO4,
Hitoshi KURUMIZAKA4, Shigehiro A. KAWASHIMA1,2, Motomu KANAI1 (1Graduate School of
Pharmaceutical Sciences, The University of Tokyo, 2JST-ERATO, 3Schrödinger K. K., 4Laboratory of Structural
Biology, Graduate School of Advanced Science and Engineering, Waseda University)

27O-ISMS18

Design and Synthesis of a Neuromedin U Receptor 2-selective PEGylated Peptide with Potent Body
Weight-Lowering Eﬀect○Yoko KANEMATSU1, Naoki NISHIZAWA1, Tomoko KAISHO1, Hiroaki NAGAI1, Taisuke MOCHIDA1,
Tomoko ASAKAWA1, Hiroshi INOOKA1, Katsuko DOTE1, Hisashi FUJITA1, Kouta MATSUMIYA1,
Hideaki HIRABAYASHI1, Junichi SAKAMOTO1, Tetsuya OHTAKI1, Shiro TAKEKAWA1, Taiji ASAMI1(1Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd.)

27O-ISMS19

Development of Glycosylated Somatostatin Having Native-like Activity and Prolonged Half-life○Hirofumi OCHIAI1, Hayato SAIJO1, Takahiro YAMAMOTO1, Yuji NISHIUCHI1, Akio KANATANI1,
Taiji SHIMODA1 (1GlyTech, Inc.)

27O-ISMS20

Innovative Synthesis Technology for the Substances of Peptide Therapeutics○Daisuke KUBO1, Kazuaki KANAI1, Rino ARAKI1, Seiji NUKUI1, Shuji FUJITA1, Yu ITO1 (1Jitsubo Co.,Ltd.)

27O-ISMS21

In Vivo Protein Knockdown by Chimeric Small-compound SNIPERs○Nobumichi OHOKA1, Yoko MORITA2, Katsunori NAGAI2, Kenichiro SHIMOKAWA2, Osamu UJIKAWA2,
Ikuo FUJIMORI2, Masahiro ITO2, Youji HAYASE2, Keiichiro OKUHIRA1, Norihito SHIBATA1,
Takayuki HATTORI1, Tomoya SAMEJIMA2, Osamu SANO2, Ryokichi KOYAMA2, Yasuhiro IMAEDA2,
Hiroshi NARA2, Nobuo CHO2, Mikihiko NAITO1 (1Division of Molecular Target and Gene Therapy Products,
National Institute of Health Sciences, 2Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.)

27O-ISMS22

Development of Protein Degradation Inducers of Oncogenic BCR-ABL Protein by Conjugation of ABL Kinase
Inhibitors and IAP Ligands○Norihito SHIBATA1, Naoki MIYAMOTO2, Katsunori NAGAI2, Kenichiro SHIMOKAWA2,
Tomoya SAMESHIMA2, Nobumichi OHOKA1, Takayuki HATTORI1, Yasuhiro IMAEDA2, Hiroshi NARA2,
Nobuo CHO2, Mikihiko NAITO1 (1Division of Molecular Target and Gene Therapy Products, National Instituteof Health Sciences, 2Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.)

27O-ISMS23

DFP-11207, a Novel Promising Antimetabolite by Using the Technology of Module Drug Discovery○Masakazu FUKUSHIMA1, Kenzo IIZUKA1, Kokoro ESHIMA1, Chung ZHANG1, Cheng JIN1,
Kiyoshi ESHIMA1 (1Division of Research and Development, Delta-Fly Pharma, Inc.)

27O-ISMS24

Similarity Implicated Exploration of the Fragment Galaxy
Gábor IMRE1, Ákos TARCSAY1, ○Fumiaki ARUGA2 (1ChemAxon Ltd., 2Patcore, Inc.)

27O-ISMS25

Machine Learning Techniques for Peptide Optimization from Sequence Information
Mark R. HANSEN1, Evgenia RAZUMOVSKAYA1, Jason HODGES1, Hugo O VILLAR1, ○Fumiaki ARUGA2(1Altoris, Inc., 2Patcore, Inc.)

27O-ISMS26

Construction of a Novel System for the Prediction of Major Clearance Pathways of Drugs only from Their 2D
Chemical Descriptors○Kazuya MAEDA1, Naomi WAKAYAMA2, Kota TOSHIMOTO3,4, Shun HOTTA3, Takashi ISHIDA3,
Yutaka AKIYAMA3, Yuichi SUGIYAMA4 (1Graduate School of Pharmaceutical Sciences, the University ofTokyo, 2Eisai Co., Ltd., 3Graduate School of Information Science and Engineering, Tokyo Institute ofTechnology, 4Sugiyama Laboratory, RIKEN Cluster for Industry Partnerships, RIKEN)– 30 –

27O-ISMS27[Cancelled]

27O-ISMS28

Establishment of a Unique Bio-conversion Platform for Drug Discovery○Shinya OKUBO1, Tomoyuki SHIBUGUCHI2, Eri ENA3, Akifumi OKUDA1 (1Technology Cross Point
Laboratory, hhc Data Creation Center, Eisai Co., Ltd., 2Neurology Tsukuba Research Department, Discovery,
Medicine Creation, Neurology Business Group, Eisai Co., Ltd., 3Analytical Research. Pharmaceutical Science& Technology Core Function Unit, Medicine Development Center, Eisai Co., Ltd.)

27O-ISMS29

A NGS-based Liquid Biopsy Gene Panel Assay with Molecular Barcode Technology○Yoshiharu SATO1, Yoji KUKITA2, Ryo MATOBA1, Kikuya KATO2 (1DNA Chip Research Inc., 2Laboratoryof Medical Genomics, Nara Institute of Science and Technology)

27O-ISMS30

Evaluation of Time Resolution in Mice Operant Learning System○Mami OIKAWA1,2, Yuichiro NOMURA2,3, Syohei IKUTA1,2, Daiki HORIE2,4, Akira AMANO4,5,
Kazuhiro SHIMONOMURA5,6, Yasuhiro SEYA5,7, Chieko KOIKE1,2,3,5 (1Grad. Sch. of Life Sciences,
2Lab. for Systems Neurosciences and Developmental Biol., 3Col. of Pharmaceut. Sci., 4Col. of Life Sci.,
5Ctr. for Systems Vision Sci., 6Col. of Sci. and Engin., Ritsumeikan Univ., 7Fac. of Human Informatics, Aichi
Shukutoku Univ.)

27O-ISMS31

Development of Highly Stereoselective Synthetic Method for 3-amino-4-hydroxytetrahydropyran via Transfer
Hydrogenation○Kazuki AZUMA1, Sayuri HIRANO1, Masatoshi YAMADA1, Etsuo KOTANI1, Takahiro KONISHI1,
Mitsuhisa YAMANO1 (1Chemical R&D Division, SPERA PHARMA, Inc.)

27O-ISMS32

Rapid and Eﬃcient Synthesis of Deuterated Cyclobutane Derivatives Using Continuous Photo Flow Chemistry○Toshiro YAMASHITA1, Hitoaki NISHIKAWA1, Tetsuji KAWAMOTO1 (1Chemistry, Research Division,
Axcelead Drug Discovery Partners, Inc.)

27O-ISMS33

Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors○Fumiyuki SHIRAI1, Yasuko KODA1, Kenichi WASHIZUKA1, Nobuko YOSHIMOTO1, Hiroo KOYAMA1,

Takehiro FUKAMI1, Yoko YASHIRODA1, Minoru YOSHIDA1, Hitomi YUKI1, Hirofumi WATANABE1,
Teruki HONMA1, Hideaki NIWA1, Shin SATO1, Takashi UMEHARA1, Mikako SHIROUZU1,
Yukiko MURAMATSU2, Haruka YOSHIDA2, Anna MIZUTANI2, Hiroyuki SEIMIYA2 (1RIKEN Center forLife Science Technologies, 2Cancer Chemotherapy Center, Japanese Foundation for Cancer Research)
27O-ISMS34

Identiﬁcation of Bis-heteroaryl Pyrazoles as Potent ALK2 (R206H) Inhibitors for Treatment of Fibrodysplasia
Ossiﬁcanas Progressiva (FOP)○Katsuhiko SEKIMATA1, Tomohiro SATO2, Naoki SAKAI3, Hisami WATANABE3, Chiemi MISHIMATSUMAGARI3, Tomonori TAGURI1, Takehisa MATSUMOTO3, Noriko HANDA4, Teruki HONMA2,
Akiko TANAKA3, Mikako SHIROUZU3, Shigeyuki YOKOYAMA4, Yoshinobu HASHIZUME5,
Kohei MIYAZONO6, Hiroo KOYAMA1 (1Drug Discovery Chemistry Platform Unit, RIKEN Center for Life
Science Technologies, 2Drug Discovery Computational Chemistry Platform Unit, RIKEN Center for Life
Science Technologies, 3Drug Discovery Structural Biology Platform Unit, RIKEN Center for Life Science
Technologies, 4Crystallographic Drug Discovery Platform Unit, RIKEN Systems and Structural Biology Center,
5RIKEN Program for Drug Discovery and Medical Technology Platforms, 6Department of Molecular Pathology,
Graduate School, The University of Tokyo)

27O-ISMS35

Identiﬁcation of Novel Pyrrolo[2,3-d]pyrimidine Derivatives as Potent HCK and FLT3-ITD Dual Inhibitors○Yasuko KODA1, Ko KIKUZATO1, Junko MIKUNI2, Akiko TANAKA2, Hitomi YUKI3, Teruki HONMA3,
Yuri TOMABECHI2, Mutsuko KUKIMOTO-NIINO2, Mikako SHIROUZU2, Fumiyuki SHIRAI1,
Hiroo KOYAMA1 (1Drug Discovery Chemistry Platform Unit, RIKEN Center for Life Science Technologies,
2Drug Discovery Structural Biology Platform Unit, RIKEN Center for Life Science Technologies, 3Drug
Discovery Computational Chemistry Platform Unit, RIKEN Center for Life Science Technologies)

27O-ISMS36

Unstructured Protein: A New Approach for Drug Discovery by Natural Product Templates
Hiroyuki KOUJI1, ○Akira KATOH1 (1Translational Chemical Biology Laboratory, Faculty of Medicine, Oita
University)

27O-ISMS37

S-033188: A Novel, First-in-Class, Orally Bioavailable Cap-dependent Endonuclease Inhibitor of Inﬂuenza○Masayoshi MIYAGAWA1, Toshiyuki AKIYAMA1, Yoshiyuki TAODA1, Kenji TAKAYA1,
Takao SHISHIDO1, Ryu YOSHIDA1, Makoto KAWAI1 (1Shionogi & Co., Ltd.)– 31 –

27O-ISMS38

Discovery of Novel 1,3-Oxazine BACE1 (β-Secretase) Inhibitors: Incorporation of an Oleﬁn Bond to Mitigate
P-gp Eﬄux Leading to Robust Aβ Reduction○Kouki FUCHINO1, Yasunori MITSUOKA1, Moriyasu MASUI1, Syuhei YOSHIDA1, Kazuo KOMANO1,
Noriyuki KUROSE1, Takahiko YAMAMOTO1, Chie UNEMURA1, Motoko HOSONO1, Hisanori ITO1,
Gaku SAKAGUCHI1, Shigeru ANDO1, Shuichi OHNISHI1, Yasuto KIDO1, Kiyotaka KOYABU1, Tamio
FUKUSHIMA1, Herman BORGHYS2, Harrie GIJSEN2, Yasuyoshi ISO1, Ken-ichi KUSAKABE1(1Shionogi & Co., Ltd., 2Janssen Pharmaceutica NV)

27O-ISMS39

Auranoﬁn, an Inhibitor of Thioredoxin Reductase, Exhibits Preferential Cytotoxicity Under Nutrient-deprived
Conditions in Human Pancreatic Cancer Cells○Takefumi ONODERA1, Isao MOMOSE1, Manabu KAWADA1,2 (1Institute of Microbial Chemistry(BIKAKEN), Numazu, 2Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology)

27O-ISMS40

Discovery of Evocalcet, a Next Generation Calcium-Sensing Receptor Agonist for the Treatment ofHyperparathyroidism○Hiroshi MIYAZAKI1, Yousuke IKEDA1, Yasunori MORITANI1, Osamu SAKURAI1, Tsutomu MIYAKE1,
Rie TSUBOTA1, Jyunko OKABE1, Masataka KURODA1, Yutaka HISADA1, Tetsuya YANAGIDA1,
Hikaru YONEDA1, Rikiya OHASHI1, Hajime FUKUDA1, Koki KOJIMA1, Takayuki KIFUJI1, Naoya SATO1,
Akiko IDEI1, Taku IGUCHI1, Tetsuya SAKAIRI1, Takehisa KAWATA2, Shin TOKUNAGA2 (1Mitsubishi
Tanabe Pharma Corporation, 2Kyowa Hakko Kirin Co., Ltd.)

27O-ISMS41

Development of Novel Non-ﬁbrate PPARα Activator for Metabolic Diseases○Keisuke TACHIBANA1, Tomohiro YUZURIHA1, Ryotaro TABATA1, Syohei FUKUDA1,
Kazuto NUNOMURA1, Tadayuki KOBAYASHI1, Kenji ISHIMOTO1, Hiroyuki MIYACHI2, Takefumi DOI1
(1Graduate School of Pharmaceutical Sciences, Osaka University, 2Lead Exploration Unit, Drug Discovery
Initiative, The University of Tokyo)

27O-ISMS42

Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitor T-3764518 as Anticancer
Agent○Keisuke IMAMURA1, Naoki TOMITA1, Youichi KAWAKITA1, Yoshiteru ITO1, Kouji ONO1, Noriyuki
NII1, Tohru MIYAZAKI1, Kazuko YONEMORI1, Michiko TAWADA1, Hiroyuki SUMI1, Yoshihiko SATOH1,
Yukiko YAMAMOTO1, Ikuo MIYAHISA1, Masako SASAKI1, Yoshinori SATOMI1, Megumi HIRAYAMA1,
Ryuichi NISHIGAKI1, Hironobu MAEZAKI1 (1Takeda Pharmaceutical Company Ltd.)

27O-ISMS43

Synthesis and Mechanistic Studies of Biakamides, Naturally-occurring Anti-austerity Agents Targeting
Mitochondria
Ryosuke ISHIDA1, Hirokazu MATSUMOTO1, Sayaka ICHII1, Masayoshi ARAI1, Motomasa KOBAYASHI1,○Naoyuki KOTOKU1,2 (1Graduate School of Pharmaceutical Sciences, Osaka University, 2College of
Pharmaceutical Sciences, Ritsumeikan University)– 32 –